Ras inhibitors + GLP-1 receptor agonists
1 paper1 finding
- 1 lab in 1 country
- Funder: Innovationsfonden
- 1 of 1 finding with company ties
- Human trial1
Outcomes
1C3M
upin humans1
1 study
C3M
upin humans1
Ras inhibitors + GLP-1 receptor agonists increase C3M in humans.
“Combination therapy (RASi + GLP-1 RA) was associated with higher urinary C3M levels compared with RASi monotherapy (P = 0.036).”
Humanspeople with T2D
American journal of physiology. Cell physiology17 Aug 2026
Latest
1 in 12 monthsAmerican Journal of Physiology Cell Physiology
Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes
Cohort study of 229 peopleType 2 diabetes